BioSpace News Archive

Ronald Renaud to serve as chairman of Kyn’s board of directors

Dr. Rathjen is the Chief Executive Officer and Managing Director of Bionomics in Adelaide, Australia; Dr. Rathjen joined the Bioasis Board in September 2017

Understanding to License Novel Investigational Synaptic Density Imaging Biomarker Technology

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical company advancing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that it has entered into a definitive agreement with several institutional and accredited investors for the purchase of 7,968,128 shares of its common stock

Innate Biologics has entered into a collaborative research agreement with The Wistar Institute, an international leader in biomedical research.

The newly accredited organizations are: Singapore Management University, Singapore and University of Florida, Gainesville, Florida

Medicare patients remain covered and continue to have access to Caris’ NGS assay for solid tumors that includes 592 genes, Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB)

- Study is among the largest and most comprehensive in multiple myeloma (MM), and will assess outcomes from 1,500 patients with MM and the t(11;14) translocation at participating International Myeloma Foundation sites globally - Study will provide insight into the relatively unknown role of genetic mutations in response to treatment and the corresponding outcomes in patients with MM

Comprehensive end-to-end services enable effective, streamlined communication with key stakeholders across all stages of drug development and commercialization

The goal is to improve vision using this revolutionary one-time treatment